Managing Injection Site Reactions on Zepbound (Tirzepatide): The HealthRX.com Step-by-Step Protocol

How common are injection site reactions on Zepbound?

The Zepbound label pools two placebo-controlled weight-management trials: 958 people on placebo and 630, 948 and 941 people on 5 mg, 10 mg and 15 mg, treated for up to 72 weeks [1]. Injection site reactions were reported by 2% of the placebo group and by 6%, 8% and 8% of the three tirzepatide groups [1]. The label groups bruising, erythema, pruritus, pain, rash and 'injection site reaction' under that one heading, so a bruise and an itchy red patch both count [1].

What does the label say about giving the injection?

Tirzepatide is injected subcutaneously once weekly, at any time of day, with or without food [1]. The labeled sites are the abdomen, the thigh and the back of the upper arm; the upper arm injection is given by another person, and sites should be rotated [1]. Zepbound comes as a vial, a prefilled single-dose pen or a single-patient-use KwikPen. The label says patients and caregivers should be trained on the specific presentation they receive, and the KwikPen is not recommended for self-administration by people who are visually impaired [1].

When is a reaction more than local?

The label separates the common local reactions above from serious hypersensitivity. Anaphylaxis and angioedema have been reported with tirzepatide after marketing, and in the pooled weight-management trials 0.1% of Zepbound-treated patients had a severe hypersensitivity reaction, compared with none on placebo [1]. Zepbound is contraindicated in people with a known serious hypersensitivity to tirzepatide or any of its excipients [1]. The label's instruction for a suspected hypersensitivity reaction is to seek medical attention promptly and discontinue Zepbound [1].